Beigene, Ltd. (NASDAQ:ONC - Get Free Report) CEO John Oyler sold 5,127 shares of the company's stock in a transaction that occurred on Friday, June 6th. The shares were sold at an average price of $252.77, for a total value of $1,295,951.79. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Beigene Stock Performance
Shares of NASDAQ ONC traded up $15.28 during midday trading on Thursday, hitting $277.69. 494,840 shares of the stock traded hands, compared to its average volume of 449,469. Beigene, Ltd. has a one year low of $141.31 and a one year high of $287.88. The company has a current ratio of 1.93, a quick ratio of 1.72 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $32.87 billion, a P/E ratio of -33.70, a PEG ratio of 7.73 and a beta of 0.30. The company's 50 day moving average is $239.06.
Beigene (NASDAQ:ONC - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $1.22 EPS for the quarter, topping analysts' consensus estimates of ($0.71) by $1.93. Beigene had a negative net margin of 25.94% and a negative return on equity of 25.12%. The company had revenue of $1.12 billion for the quarter, compared to analysts' expectations of $1.12 billion. As a group, equities research analysts forecast that Beigene, Ltd. will post -5.82 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of analysts have commented on the company. Guggenheim boosted their target price on Beigene from $348.00 to $350.00 and gave the stock a "buy" rating in a research report on Thursday, May 8th. Sanford C. Bernstein set a $259.00 price target on shares of Beigene in a report on Thursday, March 13th. JMP Securities set a $348.00 price target on Beigene in a research report on Friday, February 28th. Bank of America raised shares of Beigene from a "neutral" rating to a "buy" rating and upped their price objective for the stock from $207.00 to $320.00 in a report on Monday, March 3rd. Finally, JPMorgan Chase & Co. upped their price objective on shares of Beigene from $311.00 to $317.00 and gave the company an "overweight" rating in a research note on Monday, April 21st. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $319.00.
View Our Latest Research Report on ONC
About Beigene
(
Get Free Report)
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.
Read More
Before you consider Beigene, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beigene wasn't on the list.
While Beigene currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
